GlassScriptPhysician profile
Paul S Chang
NPI 1487627261
$51,184.53
in general payments reported to CMS, 2019-2025
57 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,831 · 2021: $8,219 · 2022: $7,825 · 2023: $10K · 2024: $2,574 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,403 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,230 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,402.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,230.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28,074.91 | 2019-2024 | Vemlidy |
| Amgen INC. | $2,629.15 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $2,474.34 | 2019-2025 | Linzess, Viberzi, Creon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,616.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,530.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $1,137.60 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $1,059.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,036.54 | 2019-2025 | |
| Lilly USA, LLC | $906.19 | 2020-2025 | Mounjaro, Lyumjev, Baqsimi |
| Bayer Healthcare Pharmaceuticals INC. | $773.84 | 2021-2025 | |
| Amarin Pharma, INC. | $772.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $771.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $766.29 | 2019-2025 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $736.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Scilex Pharmaceuticals INC. | $679.72 | 2019-2024 | Ztlido |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $651.54 | 2021-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $612.74 | 2019-2024 | Linzess |
| Radius Health, INC. | $604.86 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $566.83 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Ardelyx, INC. | $347.52 | 2024-2025 | Ibsrela |
| Allergan, INC. | $339.54 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $282.33 | 2022-2024 | Quviviq |
| Vivus LLC | $279.03 | 2021-2025 | Qsymia, Pancreaze |
| Astellas Pharma US INC | $226.90 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $213.12 | 2019-2020 | |
| Medicure Pharma INC. | $212.70 | 2020 | |
| Nestle Healthcare Nutrition INC. | $175.76 | 2021-2023 | |
| Eisai INC. | $147.40 | 2020-2024 | |
| Abiomed | $138.86 | 2023-2024 | Impella |
| Sumitomo Pharma America, INC. | $136.00 | 2024-2025 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $124.90 | 2019 | |
| Medtronic Vascular, INC. | $123.21 | 2019 | |
| Acadia Pharmaceuticals INC | $120.37 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $96.97 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $84.66 | 2021 | |
| Boston Scientific Corporation | $65.62 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Ibsa Pharma INC. | $62.94 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $62.74 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $58.59 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $57.09 | 2025 | Vowst, Zenpep |
| Kowa Pharmaceuticals America, INC. | $52.18 | 2023-2024 | Livalo, Zoryve, Seglentis |
| Globus Medical, INC. | $45.14 | 2025 | Senza |
| Sanofi Pasteur INC. | $32.01 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $31.69 | 2020-2021 | |
| Orphalan INC | $30.30 | 2024 | Cuvrior |
| Esperion Therapeutics, INC. | $30.07 | 2020-2021 | |
| Biogen, INC. | $28.16 | 2024 | Leqembi |
| Biohaven Pharmaceutical Holding Company LTD. | $23.92 | 2022 | |
| Abbott Laboratories | $23.16 | 2025 | Freestyle Libre 3 |
| Sun Pharmaceutical Industries INC. | $22.94 | 2022 | |
| Seqirus USA INC | $22.42 | 2019 | |
| Opko Pharmaceuticals, LLC | $20.74 | 2022 | |
| Optos, INC. | $20.19 | 2020 | |
| Bausch Health US, LLC | $16.64 | 2021 | |
| Progenics Pharmaceuticals, INC. | $16.03 | 2024 | |
| Endogastric Solutions, INC | $9.70 | 2020 | |
| Forte Bio-Pharma LLC | $0.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.